These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7931050)

  • 1. Warfarin resistance due to malabsorption.
    Talstad I; Gamst ON
    J Intern Med; 1994 Oct; 236(4):465-7. PubMed ID: 7931050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subtherapeutic international normalized ratio despite increasing doses of warfarin: could this be malabsorption?
    Lara LF; Delgado LL; Frazee LA; Haupt KM; Rutecki GW
    Am J Med Sci; 2000 Sep; 320(3):214-8. PubMed ID: 11014378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel revelation of warfarin resistant mechanism in roof rats (Rattus rattus) using pharmacokinetic/pharmacodynamic analysis.
    Takeda K; Ikenaka Y; Tanikawa T; Tanaka KD; Nakayama SM; Mizukawa H; Ishizuka M
    Pestic Biochem Physiol; 2016 Nov; 134():1-7. PubMed ID: 27914534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin absorption after massive small bowel resection.
    Lutomski DM; LaFrance RJ; Bower RH; Fischer JE
    Am J Gastroenterol; 1985 Feb; 80(2):99-102. PubMed ID: 3970008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of warfarin in a patient with severe short bowel syndrome.
    Kearns PJ; O'Reilly RA
    JPEN J Parenter Enteral Nutr; 1986; 10(1):100-1. PubMed ID: 3945042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary warfarin resistance.
    Diab F; Feffer S
    South Med J; 1994 Mar; 87(3):407-9. PubMed ID: 8134868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy.
    Sobieraj DM; Wang F; Kirton OC
    Pharmacotherapy; 2008 Dec; 28(12):1537-41. PubMed ID: 19025435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.
    Lee C; Coleman RW; Mungall DR
    Clin Pharm; 1987 May; 6(5):406-12. PubMed ID: 3665392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin.
    Zhang Z; Ge B; Zhou L; Lam TN; Zuo Z
    J Ethnopharmacol; 2014 Jul; 154(3):672-86. PubMed ID: 24832110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary warfarin resistance. Investigation of a rare phenomenon.
    Alving BM; Strickler MP; Knight RD; Barr CF; Berenberg JL; Peck CC
    Arch Intern Med; 1985 Mar; 145(3):499-501. PubMed ID: 3977518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High clearance of (S)-warfarin in a warfarin-resistant subject.
    Hallak HO; Wedlund PJ; Modi MW; Patel IH; Lewis GL; Woodruff B; Trowbridge AA
    Br J Clin Pharmacol; 1993 Mar; 35(3):327-30. PubMed ID: 8471414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.
    Miller JW; Skerjanec A; Knadler MP; Ghosh A; Allerheiligen SR
    Pharm Res; 2001 Jul; 18(7):1024-8. PubMed ID: 11496940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin resistance in a patient with short bowel syndrome.
    Brophy DF; Ford SL; Crouch MA
    Pharmacotherapy; 1998; 18(3):646-9. PubMed ID: 9620117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.
    Israel DS; Stotka J; Rock W; Sintek CD; Kamada AK; Klein C; Swaim WR; Pluhar RE; Toscano JP; Lettieri JT; Heller AH; Polk RE
    Clin Infect Dis; 1996 Feb; 22(2):251-6. PubMed ID: 8838180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
    Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
    Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.
    Tiseo PJ; Foley K; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):45-50. PubMed ID: 9839766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.
    Harrington DJ; Gorska R; Wheeler R; Davidson S; Murden S; Morse C; Shearer MJ; Mumford AD
    J Thromb Haemost; 2008 Oct; 6(10):1663-70. PubMed ID: 18680536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy.
    Sax MJ; Randolph WC; Peace KE; Chretien S; Frank WO; Braverman AJ; Gray DR; McCree LC; Wyle F; Jackson BJ
    Clin Pharm; 1987 Jun; 6(6):492-5. PubMed ID: 3690995
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential drug interaction between warfarin and linezolid.
    Sakai Y; Naito T; Arima C; Miura M; Qin L; Hidaka H; Masunaga K; Kakuma T; Watanabe H
    Intern Med; 2015; 54(5):459-64. PubMed ID: 25758070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.